The incidence of inclusion of the sigmoid colon and small bowel in the planning target volume in radiotherapy for prostate cancer

Strahlentherapie und Onkologie

Volumn 180, Issue 9, 2004, Pages 573-581

  De Meerleer, Gert O ^a   Villeirs, Geert M ^a   Vakaet, Luc ^a   Delrue, Louke J ^a   DeNeve, Wilfried J ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Conformal radiotherapy; Dose volume histogram; Prostate cancer; Sigmoid colon; Small bowel

Indexed keywords

LAXATIVE; MICROLAX;

ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; HUMAN; IRRADIATION; MAJOR CLINICAL STUDY; MAXIMUM PERMISSIBLE DOSE; OBSERVATION; PROSTATE; PROSTATE CANCER; RECORDING; RECTUM; SEMINAL VESICLE; SIGMOID; SMALL INTESTINE;

ADENOCARCINOMA; BODY BURDEN; COLON, SIGMOID; HUMANS; INCIDENCE; INTESTINE, SMALL; MALE; ORGAN SPECIFICITY; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIATION PROTECTION; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 4544226989     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-004-1267-5     Document Type: Article

References (39)

1. Beard CJ, Kijewski P, Bussière M, et al. Analysis of prostate and seminal vesicle motion: implications for treatment planning. Int J Radiat Oncol Biol Phys 1996;15:451-8.
2. Boersma LJ, Van den Brink M, Bruce AM, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998;41:83-92.
3. Burman C, Chui C-S, Kutcher G, et al. Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1997;39:863-73.
4. Dale E, Olsen DR, Fosså SD. Normal tissue complication probabilities correlated with late effects in the rectum after prostate conformal radiotherapy. Int J Radiat Oncol Biol Phys 1999;43:385-91.
5. Davis BJ, Cheville JC, Wilson TM, et al. Histopathologic characterization of seminal vesicle invasion in prostate cancer: implications for radiotherapeutic management. Int J Radiat Oncol Biol Phys 2001;51:Suppl 1:250.
6. Debois M, Oyen R, Maes F, et al. The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localised prostate cancer. Int J Radiat Oncol Biol Phys 1999;45:857-65.
7. De Meerleer GO, Vakaet AML, De Gersem WRT, et al. Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys 2000;47:639-48.
8. De Meerleer G, Vakaet L, De Gersem W, et al. Direct segment aperture and weight optimisation for intensity-modulated radiotherapy of prostate cancer. Strahlenther Onkol 2004;180:136-43.
9. De Neve W, De Gersem W, De Meerleer G, et al. In response to Drs. Vaarkamp and Krasin. Int J Radiat Oncol Biol Phys 2001;49:1519-20.
10. Diaz A, Roach M, Marquez C, et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localised prostate cancer. Int J Radiat Oncol Biol Phys 1994;30:323-9.
11. Fisher L, Kimose HH, Spjeldnæs N, et al. Late radiation injuries of the small bowel-management and outcome. Acta Chir Scand 1989,155:47-51.
12. Gallagher MJ, Brereton HD, Rostock RA, et al. A prospective study of treatment techniques to minimise the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation. Int J Radiat Oncol Biol Phys 1986;12:1565-73.
13. Geinitz H, Zimmermann F, Wedel E von, et al. Biochemical control after conformal, 3-dimensional radiotherapy of prostatic carcinoma. Strahlenther Onkol 2002;178:369-77.
14. Hanks GE, Hanlon AL, Epstein B, et al. Dose response in prostate cancer with 8-12 years follow-up. Int J Radiat Oncol Biol Phys 2002;54:427-35.
15. Hanks GE, Hanlon AL, Schultheiss TE, et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimisation, and future directions. Int J Radiat Oncol Biol Phys 1998;41:501-10.
16. Hanks GE, Schultheiss TE, Hanlon AL, et al. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys 1997;37:543-50.
17. Hartford AC, Niemierko A, Adams JA, et al. Conformal irradiation of the prostate: estimating long-term rectal bleeding risk using dose-volume histograms. Int J Radiat Oncol Biol Phys 1996;36:721-30.
18. Huang EH, Pollack A, Levy L, et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002;54:1314-21.
19. Jackson A, Skwarchuk MW, Zelefsky MJ, et al. Late rectal bleeding after conformal radiotherapy of prostate cancer (II): volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 2001;49:685-698.
20. Kao M-S. Intestinal complications of radiotherapy in gynecologic malignancy - clinical presentation and management. Int J Gynaecol Obstet 1995;49: S69-75.
21. Krstic RV. Illustrated encyclopedia of human histology. Berlin-Heidelberg-New York: Springer, 1984.
22. Martin T, Baltas D, Kurek R, et al. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer: a pilot study. Strahlenther Onkol 2004;180:225-32.
23. Meijer GJ, Van den Brink M, Hoogeman MS, et al. Dose-wall histograms and normalized dose-surface histograms for the rectum: a new method to analyze the dose distributions over the rectum in conformal radiotherapy. Int J Radiat Oncot Biol Phys 1999;45:1073-80.
24. Michalski JM, Purdy JA, Winter K, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000;46:391-402.
25. Mohan DS, Kupelian PA, Willoughby TR. Short-course intensity-modulated radiotherapy for localised prostate cancer with daily transabdominal ultrasound localisation of the prostate gland. Int J Radiat Oncol Biol Phys 2000;46:575-80.
26. Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001;293: 293-7.
27. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomised radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
28. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose-response: results of the M.D. Anderson phase III randomised trial. J Clin Oncol 2000;18:3904-11.
29. Scully RE, Mark EJ, McNeely WF, et al. Case records of the Massachusetts General Hospital. N Engl J Med 1997;336:1738-44.
30. Skwarchuk MW, Jackson A, Zelefsky MJ, et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose response. Int J Radiat Oncol Biol Phys 2000;47:103-13.
31. Storey MR, Pollack A, Zagars G, et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000;48:635-42.
32. Ten Haken RK, Forman JD, Heimburger DK, et al. Treatment planning issues related to prostate movement in response to differential filling of the rectum and bladder. Int J Radiat Oncol Biol Phys 1991;20: 1317-24.
33. Vaarkamp J, Krasin M. Reduction of target dose inhomogeneity in IMRT treatment planning using biologic objective functions. Int J Radiat Oncol Biol Phys 2001;49:1518-9.
34. Van Halteren HK, Gortzak E, Taal BG, et al. Surgical intervention for complications caused by late radiation damage of the small bowel: a retrospective analysis. Eur J Surg Oncol 1993;19:336-41.
35. Wachter S, Gerstner N, Goldner G, et al. Rectal sequelae after conformal radiotherapy of prostate cancer: dose volume histograms as predictive factors. Radioth Oncol 2001;59:65-70.
36. Wachter-Gerstner N, Wachter S, Goldner G, et al. Biochemical response after 3-D conformal radiotherapy of localized prostate cancer to a total dose of 66 Gy. Strahlenther Onkol 2002;178:542-7.
37. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity-modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int 3 Radiat Oncol Biol Phys 2002;53:1117-23.
38. Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 1997;49:Suppl 3A:38-45.
39. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer, Int J Radiat Oncol Biol Phys 1998;41:491-500.